Cognitive Dysfunction
📧 Sign up to get email alerts when something new happens for Cognitive Dysfunction.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-05EMA Authorised: Leqembi (Lecanemab) — Eisai GmbH
The EMA has authorised Leqembi (lecanemab) for cognitive dysfunction and Alzheimer's disease, with Eisai GmbH as the marketing authorization…
-
EMA approval · 2026-02-26EMA Authorised: Kisunla (donanemab) — Eli Lilly Nederland B.V.
EMA authorised Kisunla (donanemab) for Alzheimer's disease and cognitive dysfunction in the European Union. Eli Lilly Nederland B.V. is the …